ACRIN-DSC-MR-Brain

Summary

Staging With MR Perfusion Imaging and MR Spectroscopy. ACRIN 6677 is conducted in collaboration with RTOG 0625: A Randomized Trial of Bevacizumab With Temozlomide in Recurrent Glioblastoma 

This was a multicenter phase 2 clinical trial by the ACRIN Cooperative Group (now part of ECOG-ACRIN) and the RTOG Cooperative Group  (now part of NRG) using .....

The objective of the ACRIN 6677 was to ..... Eligible patients were those 18 years and older with a histologically proven intracranial glioblastoma or gliosarcoma. There must be pathologic or imaging confirmation of tumor progression or regrowth.

Primary Aim Findings: To assess the agreement between local interpretation and central interpretation of the standard MRI on the 6-month progression-free survival and to estimate the accuracy of local interpretation on the 6-month progression-free survival using central review as the reference standard.

Advanced Imaging Component Objectives:  To assess the potential role of perfusion MRI and MR spectroscopy imaging as an early indicator of response to the therapy after two weeks following initiation of treatment with bevacizum and to assess the potential role of perfusion MRI and MR spectroscopy imaging as a prognostic indicator based on images taken before treatment, 2 weeks following initiation of protocol treatment, and after every 2 cycles of treatment.

Acknowledgements

This shared data set was provided in collaboration with the American College of Radiology Core Lab. Many thanks are due to the ACRIN 6677 trial team, and all the patients participating in the study.

This study was supported by the ACRIN Cooperative Group (now part of ECOG-ACRIN) and the RTOG Cooperative Group  (now part of NRG) which received funding from the National Cancer Institute through UXX CAXXXXXX and UXX CAXXXXXX.